MD1541Z - Метод лечения инфекции вирусом SARS-CoV-2 средней формы - Google Patents
Метод лечения инфекции вирусом SARS-CoV-2 средней формы Download PDFInfo
- Publication number
- MD1541Z MD1541Z MDS20200140A MDS20200140A MD1541Z MD 1541 Z MD1541 Z MD 1541Z MD S20200140 A MDS20200140 A MD S20200140A MD S20200140 A MDS20200140 A MD S20200140A MD 1541 Z MD1541 Z MD 1541Z
- Authority
- MD
- Moldova
- Prior art keywords
- day
- extract
- extract10
- sars
- days
- Prior art date
Links
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 15
- 208000015181 infectious disease Diseases 0.000 title abstract description 4
- 239000000284 extract Substances 0.000 claims abstract description 14
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 240000003291 Armoracia rusticana Species 0.000 claims abstract description 9
- 235000011330 Armoracia rusticana Nutrition 0.000 claims abstract description 9
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 9
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 9
- 241001426527 Rhaponticum Species 0.000 claims abstract description 9
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 9
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 8
- 240000006891 Artemisia vulgaris Species 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 240000004371 Panax ginseng Species 0.000 claims abstract description 7
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 7
- 235000008434 ginseng Nutrition 0.000 claims abstract description 7
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 6
- 240000007049 Juglans regia Species 0.000 claims abstract description 6
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 6
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 6
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 6
- 239000001168 astaxanthin Substances 0.000 claims abstract description 6
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000008213 purified water Substances 0.000 claims abstract description 6
- 235000020234 walnut Nutrition 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 5
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 5
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 5
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 5
- 229960005489 paracetamol Drugs 0.000 claims abstract description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 4
- 235000019441 ethanol Nutrition 0.000 claims abstract description 4
- 235000012054 meals Nutrition 0.000 claims abstract description 4
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960004626 umifenovir Drugs 0.000 claims abstract description 4
- 235000004355 Artemisia lactiflora Nutrition 0.000 claims abstract description 3
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 3
- 244000067505 Xanthium strumarium Species 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 17
- 230000009385 viral infection Effects 0.000 claims description 9
- 239000001522 artemisia absinthium l. herb extract Substances 0.000 claims description 2
- 235000020710 ginseng extract Nutrition 0.000 claims description 2
- 229940119569 wormwood extract Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 3
- 208000035473 Communicable disease Diseases 0.000 abstract description 2
- 241001506766 Xanthium Species 0.000 abstract 1
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000025721 COVID-19 Diseases 0.000 description 3
- 241000758789 Juglans Species 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 208000010470 Ageusia Diseases 0.000 description 2
- 206010002653 Anosmia Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CKGWFZQGEQJZIL-UHFFFAOYSA-N amylmetacresol Chemical compound CCCCCC1=CC=C(C)C=C1O CKGWFZQGEQJZIL-UHFFFAOYSA-N 0.000 description 1
- 229960005213 amylmetacresol Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Изобретение относится к медицине, в частности к инфекционным заболеваниям, и может быть использовано для лечения инфекции вирусом SARS-CoV-2 средней формы.Сущность изобретения состоит в том, что принимают per os, парацетамол 500 мг 4 раза в день, умифеновир 100 мг 4 раза в день, ежедневно, в течение 5…7 дней, также принимают за 15…20 мин до еды, по 50 мл 3 раза в день, в течение 15…21 дня, композицию на основе этилового спирта 96,4%, которая содержит сухие экстракты полыни обыкновенной (Artemisia vulgaris), дурнишника обыкновенного (Xanthium strumarium), корня марала (Rhaponticum carthamoides), кожуры грецкого ореха (Juglans regia), хрена обыкновенного (Armoracia rusticana), любистока (Levisticum officinale), женьшеня (Panax ginseng), порошка таксифолина и астаксантина, при соотношении 1:4-1:5, и очищенной воды до получения 32…35%-го спиртового раствора, при следующем соотношении компонентов, в масс.%:экстракт полыни обыкновенной13 ± 2экстракт дурнишника обыкновенного10 ± 2 экстракт кореня марала10 ± 2экстракт скорлупы грецкого ореха10 ± 2экстракт хрен обыкновенного10 ± 2экстракт любистока10 ± 2экстракт женьшеня11 ± 2порошок таксифолина13 ± 2порошок астаксантина13 ± 2вода очищеннаядо получения 32…35%-го спиртового раствора.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20200140A MD1541Z (ru) | 2020-10-27 | 2020-10-27 | Метод лечения инфекции вирусом SARS-CoV-2 средней формы |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20200140A MD1541Z (ru) | 2020-10-27 | 2020-10-27 | Метод лечения инфекции вирусом SARS-CoV-2 средней формы |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1541Y MD1541Y (ru) | 2021-06-30 |
| MD1541Z true MD1541Z (ru) | 2022-01-31 |
Family
ID=76633495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20200140A MD1541Z (ru) | 2020-10-27 | 2020-10-27 | Метод лечения инфекции вирусом SARS-CoV-2 средней формы |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1541Z (ru) |
-
2020
- 2020-10-27 MD MDS20200140A patent/MD1541Z/ru active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MD1541Y (ru) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roxas et al. | Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. | |
| CN102245194B (zh) | 用于预防和治疗病毒感染的组合物 | |
| WO2024140866A1 (zh) | 麦角硫因在制备预防或抑制由乙醛引起的细胞损伤产品中的应用 | |
| US20130131000A1 (en) | Composition Comprising Ligustroflavone, Rhoifolin and Hyperin and Its Pharmaceutical Application | |
| WO2023241662A1 (zh) | 一种复方氨酚那敏颗粒及其制备工艺 | |
| MD1541Z (ru) | Метод лечения инфекции вирусом SARS-CoV-2 средней формы | |
| CN114469930A (zh) | 马兜铃酸IVa在制备抗组胺或治疗肺炎药物中的应用 | |
| TW202203946A (zh) | 用於人或動物之慢性或急性之病毒感染症及/或敗血症之預防或治療的組成物 | |
| JP2001122795A (ja) | 感染性疾患予防・治療剤 | |
| CN111821305A (zh) | 一种匹洛那韦利托那韦制剂及其适应症 | |
| MD1629Z (ru) | Фитотерапевтическая пищевая добавка против SARS-CoV-2 | |
| CN105853417B (zh) | 乌头碱在治疗红斑狼疮中的应用 | |
| MD1533Z (ru) | Пищевая фитотерапевтическая добавка антиSARS-CoV-2 | |
| MD1531Z (ru) | Пищевая фитотерапевтическая добавка антиSARS-CoV-2 | |
| MD1532Z (ru) | Пищевая фитотерапевтическая добавка антиSARS-CoV-2 | |
| JPS5938207B2 (ja) | 腎疾患治療剤 | |
| EP4216944B1 (de) | Neues therapiekonzept für die behandlung von corona-infektionen, insbesondere covid-19-infektionen | |
| CN100371015C (zh) | 一种抗病毒的中草药产品 | |
| RU2442599C2 (ru) | ГОМЕОПАТИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО И БИОЛОГИЧЕСКИ АКТИВНАЯ ДОБАВКА К ПИЩЕ, СОДЕРЖАЩИЕ Nisylen, Сера, Euphrasia, Belladonna И/ИЛИ Mercurius solubilis | |
| ZA200709069B (en) | Pharmaceutical Formulation for treatment of acquired immune deficiency syndrome (AIDS). Obtaining procedure | |
| RU2234922C2 (ru) | Антигриппозный комплексный препарат | |
| KR20070097274A (ko) | 니실렌, 세파, 유프라시아, 벨라도나 및/또는 메르쿠리어스솔루빌리스를 포함하는 드러그 및/또는 식품보충제 | |
| GB2622661A (en) | Composition | |
| CN101045127A (zh) | 含Nisylen、洋葱、小米草、颠茄和/或稀释水银的药物和/或食品增补剂 | |
| EP2552466A1 (de) | Zusammensetzung enthaltend bestandteile aus sonnenhut, holunder und kamille zur behandlung von erkältungskrankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued |